Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/4031

Title: The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males
Authors: Sargentini-Maier, Maria Laura
Rolan, Paul
Connell, John
Tytgat, Dominique
Pigeolet, Etienne
Riethuisen, Jean-Michel
Stockis, Armel
Issue Date: 2007
Abstract: Aims The objective of the study was to evaluate the pharmacokinetics (and how they are affected by food), CNS pharmacodynamics and the adverse event profile of brivaracetam after single increasing doses. Methods Healthy males (n = 27, divided into three alternating panels of nine subjects) received two different single oral doses of brivaracetam (10-1400 mg) and one dose of placebo during three periods of a randomized, double-blind, placebo-controlled study. The effect of food on its pharmacokinetics was assessed using a standard two-way crossover design in a further eight subjects who received two single oral doses of brivaracetam (150 mg) in the fasting state and after a high fat meal. Results Adverse events, none of which were serious, were mostly CNS-related and included somnolence, dizziness, and decreased attention, alertness, and motor control. Their incidence, severity and duration were dose-related. The maximum tolerated dose was established to be 1000 mg. Severe somnolence lasting 1 day occurred in one subject following 1400 mg. Brivaracetam was rapidly absorbed under fasting conditions, with a median t(max) of approximately 1 h. C-max was dose-proportional from 10 to1400 mg, whereas AUC deviated from dose linearity above 600 mg. A high-fat meal had no effect on AUC (point estimate 0.99, 90%CI: 0.92-1.07) but delayed t(max) (3 h) and decreased C-max (point estimate 0.72, 90%CI: 0.66-0.79). Conclusions Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose. Brivaracetam was found to have desirable pharmacokinetic properties. The most common adverse events were somnolence and dizziness.
Notes: UCB Bioprod SA, Res & Dev, B-1420 Braine lAlleud, Belgium. Medeval Ltd, Manchester, Lancs, England. Univ Adelaide, Adelaide, SA 5005, Australia. Univ Hasselt, Dept Stat, Diepenbeek, Belgium.Sargentini-Maier, ML, UCB Bioprod SA, Res & Dev, Chemin Foriest, B-1420 Braine lAlleud, Belgium.laura.maier@ucb-group.com
URI: http://hdl.handle.net/1942/4031
ISI #: 000246576800006
ISSN: 0306-5251
Category: A1
Type: Journal Contribution
Validation: ecoom, 2008
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.